BR112018072915A2 - peptídeo cíclico isolado e composição farmacêutica - Google Patents

peptídeo cíclico isolado e composição farmacêutica

Info

Publication number
BR112018072915A2
BR112018072915A2 BR112018072915-9A BR112018072915A BR112018072915A2 BR 112018072915 A2 BR112018072915 A2 BR 112018072915A2 BR 112018072915 A BR112018072915 A BR 112018072915A BR 112018072915 A2 BR112018072915 A2 BR 112018072915A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
cyclic peptide
present
relates
pcd
Prior art date
Application number
BR112018072915-9A
Other languages
English (en)
Inventor
Karoyan Philippe
Original Assignee
Sorbonne Universite
Centre National De La Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorbonne Universite, Centre National De La Recherche Scientifique filed Critical Sorbonne Universite
Publication of BR112018072915A2 publication Critical patent/BR112018072915A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção se refere a peptídeos cíclicos miméticos do domínio de ligação c-terminal de tsp-1. a presente invenção também se refere ao uso desses peptídeos cíclicos como agonistas de cd47 e sua capacidade para desencadear morte celular programada (pcd). a presente invenção se refere ainda a uma composição farmacêutica para uso no tratamento de doenças associadas a defeitos na pcd, tais como cânceres e distúrbios imunológicos (incluindo inflamação crônica), e que compreende pelo menos um peptídeo cíclico de acordo com a invenção.
BR112018072915-9A 2016-05-10 2017-05-10 peptídeo cíclico isolado e composição farmacêutica BR112018072915A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305543.7 2016-05-10
EP16305543.7A EP3243522A1 (en) 2016-05-10 2016-05-10 Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
PCT/EP2017/061233 WO2017194634A1 (en) 2016-05-10 2017-05-10 Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death

Publications (1)

Publication Number Publication Date
BR112018072915A2 true BR112018072915A2 (pt) 2019-02-19

Family

ID=56014941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072915-9A BR112018072915A2 (pt) 2016-05-10 2017-05-10 peptídeo cíclico isolado e composição farmacêutica

Country Status (12)

Country Link
US (1) US11306124B2 (pt)
EP (2) EP3243522A1 (pt)
JP (1) JP7166933B2 (pt)
KR (1) KR102566709B1 (pt)
CN (1) CN109328067B (pt)
AU (1) AU2017263038B2 (pt)
BR (1) BR112018072915A2 (pt)
CA (1) CA3023670A1 (pt)
IL (1) IL262805B2 (pt)
MX (1) MX2018013622A (pt)
WO (1) WO2017194634A1 (pt)
ZA (1) ZA201808186B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019138367A1 (en) 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
EP3650036A1 (en) 2018-11-06 2020-05-13 Sorbonne Universite Synthetic peptides inducing immunogenic cell death
BR112021008781A2 (pt) 2018-11-08 2021-08-03 Aurigene Discovery Technologies Limited combinação de inibidores de cd-47 de pequena molécula com outros agentes anticâncer
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
JP2023502745A (ja) * 2019-11-21 2023-01-25 アンナチュラル・プロダクツ・インコーポレイテッド 細胞透過性環状ペプチドおよびその使用
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
CN112480231B (zh) * 2020-12-14 2022-05-24 上海交通大学 一种生物活性肽kqslppglavkdlk及其制备方法和应用
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104519898A (zh) * 2012-06-06 2015-04-15 国家健康与医学研究院 用于治疗癌症的方法和药物组合物

Also Published As

Publication number Publication date
AU2017263038B2 (en) 2021-10-21
IL262805B2 (en) 2023-12-01
CA3023670A1 (en) 2017-11-16
WO2017194634A1 (en) 2017-11-16
US11306124B2 (en) 2022-04-19
US20190135865A1 (en) 2019-05-09
EP3243522A1 (en) 2017-11-15
ZA201808186B (en) 2022-04-28
JP7166933B2 (ja) 2022-11-08
IL262805B1 (en) 2023-08-01
JP2019518737A (ja) 2019-07-04
KR102566709B1 (ko) 2023-08-11
EP3454880B1 (en) 2022-01-26
CN109328067A (zh) 2019-02-12
EP3454880A1 (en) 2019-03-20
IL262805A (en) 2018-12-31
CN109328067B (zh) 2023-06-16
AU2017263038A1 (en) 2018-12-20
KR20190016026A (ko) 2019-02-15
MX2018013622A (es) 2019-08-01

Similar Documents

Publication Publication Date Title
BR112018072915A2 (pt) peptídeo cíclico isolado e composição farmacêutica
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
CL2018003438A1 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos.
BR112019004764A2 (pt) inibidores bicíclicos fundidos da interação menina-mll
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
DOP2017000171A (es) Proteínas de unión a icos.
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
BR112018002824A2 (pt) anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
PH12019500596A1 (en) Recombinant binding proteins and their use
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
BR112016002199B8 (pt) Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
BR122020006907B8 (pt) Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112016014969A2 (pt) polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
PE20160528A1 (es) Anticuerpos
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
BR112017001782A2 (pt) fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
WO2020131586A3 (en) Methods for identifying neoantigens
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
BR112017011530A2 (pt) polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]